Display options
Cite
Galeffi P, Lombardi A, Pietraforte I, et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med. 2006;4:39doi: 10.1186/1479-5876-4-39.
Galeffi, P., Lombardi, A., Pietraforte, I., Novelli, F., Di Donato, M., Sperandei, M., Tornambé, A., Fraioli, R., Martayan, A., Natali, P. G., Benevolo, M., Mottolese, M., Ylera, F., Cantale, C., & Giacomini, P. (2006). Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. Journal of translational medicine, 439. https://doi.org/10.1186/1479-5876-4-39
Galeffi, Patrizia, et al. "Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems." Journal of translational medicine vol. 4 (2006): 39. doi: https://doi.org/10.1186/1479-5876-4-39
Galeffi P, Lombardi A, Pietraforte I, Novelli F, Di Donato M, Sperandei M, Tornambé A, Fraioli R, Martayan A, Natali PG, Benevolo M, Mottolese M, Ylera F, Cantale C, Giacomini P. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med. 2006 Sep 29;4:39. doi: 10.1186/1479-5876-4-39. PMID: 17010186; PMCID: PMC1592514.
Copy Download .nbib Format: NLM
Share it on

J Transl Med. 2006 Sep 29;4:39. doi: 10.1186/1479-5876-4-39.

Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems.

Journal of translational medicine

Patrizia Galeffi, Alessio Lombardi, Immacolata Pietraforte, Flavia Novelli, Monica Di Donato, Maria Sperandei, Andrea Tornambé, Rocco Fraioli, Aline Martayan, Pier Giorgio Natali, Maria Benevolo, Marcella Mottolese, Francisco Ylera, Cristina Cantale, Patrizio Giacomini

Affiliations

  1. ENEA BIOTEC-GEN, CR Casaccia Via Anguillarese 301, 00060 Rome, Italy. [email protected]

PMID: 17010186 PMCID: PMC1592514 DOI: 10.1186/1479-5876-4-39

Abstract

BACKGROUND: Aberrant signaling by ErbB-2 (HER 2, Neu), a member of the human Epidermal Growth Factor (EGF) receptor family, is associated with an aggressive clinical behaviour of carcinomas, particularly breast tumors. Antibodies targeting the ErbB-2 pathway are a preferred therapeutic option for patients with advanced breast cancer, but a worldwide deficit in the manufacturing capacities of mammalian cell bioreactors is foreseen.

METHODS: Herein, we describe a multi-platform approach for the production of recombinant Single chain Fragments of antibody variable regions (ScFvs) to ErbB-2 that involves their functional expression in (a) bacteria, (b) transient as well as stable transgenic tobacco plants, and (c) a newly developed cell-free transcription-translation system.

RESULTS: An ScFv (ScFv800E6) was selected by cloning immunoglobulin sequences from murine hybridomas, and was expressed and fully functional in all the expression platforms, thereby representing the first ScFv to ErbB-2 produced in hosts other than bacteria and yeast. ScFv800E6 was optimized with respect to redox synthesis conditions. Different tags were introduced flanking the ScFv800E6 backbone, with and without spacer arms, including a novel Strep II tag that outperforms conventional streptavidin-based detection systems. ScFv800E6 was resistant to standard chemical radiolabeling procedures (i.e. Chloramine T), displayed a binding ability extremely similar to that of the parental monovalent Fab' fragment, as well as a flow cytometry performance and an equilibrium binding affinity (Ka approximately 2 x 10(8) M(-1)) only slightly lower than those of the parental bivalent antibody, suggesting that its binding site is conserved as compared to that of the parental antibody molecule. ScFv800E6 was found to be compatible with routine reagents for immunohistochemical staining.

CONCLUSION: ScFv800E6 is a useful reagent for in vitro biochemical and immunodiagnostic applications in oncology, and a candidate for future in vivo studies.

References

  1. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9022-6 - PubMed
  2. Nature. 1993 Dec 2;366(6454):469-72 - PubMed
  3. Nat Biotechnol. 1997 Jan;15(1):79-84 - PubMed
  4. Proc Natl Acad Sci U S A. 1997 May 13;94(10):4937-42 - PubMed
  5. EMBO J. 1997 Sep 15;16(18):5608-17 - PubMed
  6. J Mol Biol. 1998 Jul 3;280(1):117-27 - PubMed
  7. Curr Opin Biotechnol. 1998 Oct;9(5):534-48 - PubMed
  8. J Immunol Methods. 1998 Nov 1;220(1-2):69-75 - PubMed
  9. J Biochem. 1999 Feb;125(2):328-33 - PubMed
  10. Plant Mol Biol. 2000 Mar;42(4):583-90 - PubMed
  11. Oncogene. 2000 Dec 27;19(56):6550-65 - PubMed
  12. Clin Cancer Res. 2002 Jun;8(6):1710-9 - PubMed
  13. Nat Biotechnol. 2002 Aug;20(8):777-9 - PubMed
  14. Cell Res. 2003 Feb;13(1):35-48 - PubMed
  15. J Immunol Methods. 2003 Jul;278(1-2):95-104 - PubMed
  16. Plant J. 1992 Jul;2(4):549-57 - PubMed
  17. Hybridoma. 1992 Aug;11(4):519-27 - PubMed
  18. Nat Rev Genet. 2003 Oct;4(10):794-805 - PubMed
  19. Breast Cancer Res Treat. 2003 Dec;82(3):155-64 - PubMed
  20. Biotechnol Bioeng. 2004 Jan 20;85(2):122-9 - PubMed
  21. Biotechnol Annu Rev. 2004;10:1-30 - PubMed
  22. Vaccine. 2005 Mar 7;23(15):1823-7 - PubMed
  23. Protein Expr Purif. 2005 Nov;44(1):10-5 - PubMed
  24. J Immunol. 2006 Apr 15;176(8):4869-79 - PubMed
  25. Plant Mol Biol. 1991 Oct;17(4):865-74 - PubMed
  26. Int J Cancer. 1987 Jun 15;39(6):729-36 - PubMed

Publication Types